Status:
COMPLETED
A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma
Lead Sponsor:
Vectura Limited
Conditions:
Wheezing
Reactive Airway Disease
Eligibility:
All Genders
4-8 years
Phase:
PHASE1
Brief Summary
The primary objective of this study is to evaluate budesonide levels in the blood following inhalation of single doses of VR647 Inhalation Suspension in children with wheezing, reactive airway disease...
Eligibility Criteria
Inclusion
- Key
- Male or pre-menarchal female subjects.
- Aged 4 to 8 years, inclusive.
- Diagnosis of wheezing, reactive airway disease or mild asthma confirmed by a physician at least 3 months prior to screening.
- Wheezing, reactive airway disease or mild asthma controlled by intermittent or regular non-steroidal medications commonly used for asthma, such as short-acting β2-agonists (SABAs) or leukotriene receptor antagonists (LTRAs), for a minimum of 28 days prior to the Screening Visit.
- Body weight ≥15 kg.
- Subject is able to demonstrate the ability to use the VR647 Inhalation System and the conventional jet nebulizer effectively during training.
- Key
Exclusion
- Clinically relevant abnormality or medical condition (other than wheezing, reactive airway disease or mild asthma) identified at the screening assessment that, in the opinion of the investigator, could interfere with the objectives of the trial or the safety of the subject. The sponsor's medical officer should be consulted in case of any doubt.
- Life-threatening asthma, defined as a history of asthma episode(s) requiring intubation, and/or associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episodes.
- Subjects currently using long-acting β2-agonists.
- Use of the following prescription medications within 28 days prior to the first treatment day: corticosteroids by any route and drugs that inhibit cytochrome P450 3A4.
Key Trial Info
Start Date :
December 18 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 27 2018
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT03421730
Start Date
December 18 2017
End Date
March 27 2018
Last Update
October 21 2019
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Vectura Study Site 0003
Colorado Springs, Colorado, United States, 80907
2
Vectura Study Site 0002
Raleigh, North Carolina, United States, 27607
3
Vectura Study Site 0001
Tulsa, Oklahoma, United States, 74136